Sym#

Related by string. * * *

Related by context. All words. (Click for frequent words.) 75 IMA# 75 Azedra 75 oral prodrug 74 CCX# 74 CEQ# 74 HuMax EGFr 73 Nanobody 73 PEG SN# 73 ganetespib 73 TG# [003] 73 Alocrest 73 angiogenesis inhibitor 73 ENMD # 73 Traficet EN 72 BAY #-# 72 orally bioavailable 72 AEG# 72 Phase Ib study 72 NXL# 72 Blinatumomab 72 INCB# [001] 72 tanespimycin 72 CBLC# 71 PDE4 inhibitor 71 Carfilzomib 71 mertansine 71 nucleoside analog 71 huC# DM4 71 Dapagliflozin 71 XmAb# 71 R#/MEM # 71 GRNVAC1 71 HGS ETR2 71 liposomal formulation 71 Archexin 71 JAK inhibitor 71 YONDELIS 71 EndoTAG TM -1 71 alvespimycin 71 favorable pharmacokinetic profile 71 HGS ETR1 71 pan HDAC inhibitor 71 preclinically 71 Proxinium TM 71 OMP #M# 71 IgG1 antibody 71 HuMax CD4 71 PRT# 71 Seliciclib 71 PXD# 71 Tesetaxel 71 Guanilib 71 CA4P 70 Tyrima 70 cannabinor 70 Bezielle 70 RGB # 70 proteasome inhibitor 70 Dasatinib 70 HuMax CD# 70 obatoclax 70 cilengitide 70 radiation sensitizer 70 protein kinase inhibitor 70 ZK EPO 70 MEK inhibitor 70 decitabine 70 Symadex 70 phase IIb clinical 70 solithromycin 70 preclinical efficacy 70 PSMA ADC 70 CRLX# 70 mapatumumab 70 Imprime PGG 70 MAGE A3 ASCI 70 eltrombopag 70 DXL# 70 Pertuzumab 70 pertuzumab 70 humanized antibody 70 SAR# [002] 70 Vidaza azacitidine 69 orally dosed 69 depsipeptide 69 elotuzumab 69 Litx 69 OncoVEX GM CSF 69 DermaVir Patch 69 Tarvacin TM 69 CYC# 69 BRAF inhibitor 69 Tezampanel 69 anticancer compound 69 OXi# 69 OncoVEX 69 teriflunomide 69 MLN# 69 GRN#L 69 humanized anti 69 CR# vcMMAE 69 Romidepsin 69 Safinamide 69 CYT# 69 Phase Ib clinical 69 VA# [002] 69 TRO# 69 LY# [002] 69 BiTE 69 cMET 69 ocular formulation 69 Aplidin R 69 sorafenib Nexavar 69 polymerase inhibitor 69 selective androgen receptor modulator 69 MEK inhibitors 69 phase IIa clinical 69 investigational monoclonal antibody 69 PSN# [002] 69 Vandetanib 69 Elagolix 69 HuLuc# 69 docetaxel Taxotere ® 69 ESBA# 69 JAK3 69 HQK 69 enzastaurin 69 pharmacodynamic profile 69 R roscovitine 69 Tanespimycin 69 MGd 69 HGS# 69 vorinostat 68 SRT# [003] 68 DAVANAT 68 Annamycin 68 TG# [001] 68 receptor tyrosine kinase inhibitor 68 Cannabinor 68 GAMMAGARD 68 CD# monoclonal antibody 68 Enzastaurin 68 GLPG# 68 iSONEP 68 pomalidomide 68 ANG# 68 Xanafide 68 Epratuzumab 68 Factor VIIa 68 Sapacitabine 68 seliciclib 68 Amrubicin 68 MGCD# [001] 68 selective kinase inhibitor 68 myelofibrosis polycythemia vera 68 NEUGENE 68 tezampanel 68 Aurora kinase 68 novel peptide 68 HCV protease inhibitor 68 Triolex 68 SCH # 68 vascular disrupting agent 68 EOquin TM 68 histone deacetylase HDAC inhibitor 68 Aflibercept 68 vidofludimus 68 elacytarabine 68 evaluating tivozanib 68 RAV# 68 GW# [003] 68 Cetrorelix 68 forodesine 68 fosbretabulin 68 radezolid 68 indibulin 68 flavopiridol 68 orally administered inhibitor 68 Laquinimod 68 APTIVUS 68 Phase Ib II 68 JAK2 inhibitor 68 investigational humanized monoclonal antibody 68 PNT# 68 CIMZIA TM 68 sodium glucose cotransporter 68 LY# [003] 68 PI3K inhibitor 68 Bortezomib 68 pharmacokinetic PK study 68 Bavituximab 68 FOLOTYN ® 68 NGX# 68 PROCHYMAL 68 XL# XL# 68 hA# 68 VitiGam 68 JAK1 68 Ceflatonin 68 humanized monoclonal antibody 68 trabectedin 68 Virulizin ® 68 INCB# [003] 68 HCD# [002] 68 OHR/AVR# 68 EOquin 68 Telbivudine 68 ZOLINZA 68 docetaxel Taxotere R 68 Phase 1a clinical 68 AP# [003] 67 PRTX 67 VAPRISOL 67 anti EGFR antibody 67 Trastuzumab 67 GRN# 67 TPI ASM8 67 Talabostat 67 Gleevec resistant 67 ATL# [001] 67 EGFr 67 Atiprimod 67 Aplidin 67 Zalypsis 67 PEGylated Fab fragment 67 riociguat 67 IRX 2 67 bortezomib Velcade 67 BAL# [002] 67 Nanobody ® 67 Glufosfamide 67 AVE# 67 Radezolid 67 PS# [001] 67 PF # [001] 67 NVA# 67 PrevOnco 67 Aclidinium 67 Pazopanib 67 immunomodulator 67 ISIS # 67 Ophena 67 Golimumab 67 RhuDex ® 67 CYT# potent vascular disrupting 67 BRIM2 67 Mipomersen 67 Anticalins 67 TELCYTA 67 metaglidasen 67 CORT # 67 Tamibarotene 67 Kahalalide F 67 ELACYT 67 PEGylated 67 #I TM# 67 Doxorubicin 67 Elesclomol 67 #D#C# 67 PLK1 SNALP 67 PROMACTA 67 thymalfasin 67 TLK# 67 ongoing Phase 1b 67 IMC #B 67 thalidomide Thalomid 67 somatostatin analogue 67 Ceftaroline 67 PRX# 67 Linaclotide 67 SAR# [004] 67 RhD positive 67 Synavive 67 cleavable linker 67 systemically administered 67 Anticalins ® 67 polyclonal antibody 67 PD LID 67 virus HCV protease inhibitor 67 eniluracil 67 Zolinza 67 cancer immunotherapies 67 JAK2 inhibitors 67 Phase 2a Clinical Trial 67 APOPTONE 67 Panzem R NCD 67 Pimavanserin 67 Randomized Phase 67 Panzem 67 Hepatocellular Carcinoma HCC 67 Aliskiren 67 busulfan 67 pralatrexate 67 MT# MEDI 67 JAK inhibitors 67 Plicera 67 ALN VSP 67 anti angiogenic agent 67 HCV protease 67 rNAPc2 67 NOX E# 67 Vicinium TM 67 rFIXFc 67 proteasome inhibitors 67 EZN 67 subcutaneous formulation 67 Antitumor Activity 67 axitinib 67 dexpramipexole 67 SNT MC# 67 AZILECT R 67 PNP inhibitor 67 Maribavir 67 CCR9 antagonist 67 TBC# 67 therapeutic monoclonal antibody 67 Arikace 67 antibody fragment 67 Phase Ib 67 TACI Ig 67 oxidative stress inducer 67 octreotide acetate 67 Quinamed 67 polymerase inhibitors 67 Elotuzumab 67 IAP inhibitor 67 GAP #B# 67 Dalbavancin 67 Phase 2a trial 67 SPC# [001] 67 CD# antibody [001] 67 IAP inhibitors 66 Liposomal 66 Tarvacin 66 ALN TTR# 66 CCR5 antagonist 66 CDK inhibitor 66 trastuzumab Herceptin 66 Preclinical studies suggest 66 peptibody 66 RLY# 66 EpCAM 66 triphendiol 66 tigecycline 66 CoFactor 66 Aurora Kinase 66 Phase #/#a 66 INT# [002] 66 bevacizumab Avastin ® 66 phase IIb 66 Nanobodies 66 Amigal 66 Hsp# Inhibitor 66 sapacitabine 66 KB# [002] 66 Omacetaxine 66 Interferon alpha 66 administered subcutaneously 66 sunitinib malate 66 multicenter Phase II 66 huN# DM1 66 zileuton 66 Cloretazine ® 66 nitazoxanide 66 ONCONASE R 66 vinca alkaloid 66 alkylating agent 66 CTAP# Capsules 66 ApoB SNALP 66 milatuzumab 66 OMP #R# 66 torezolid phosphate 66 HGS ETR1 mapatumumab 66 Ocrelizumab 66 Angiocept 66 AeroLEF TM 66 daptomycin 66 integrase inhibitor 66 systemic RNAi therapeutic 66 ospemifene 66 MYDICAR ® 66 targeted radiotherapeutic 66 drug conjugate 66 LEX System 66 LHRH antagonists 66 tyrosine kinase inhibitor 66 Civacir 66 pegylated liposomal doxorubicin 66 GV# [001] 66 Bendavia 66 Relivar 66 neratinib 66 renin inhibitor 66 Pralatrexate 66 Tasimelteon 66 immunotherapeutic agent 66 Pharmacokinetics PK 66 ON #.Na 66 Velcade bortezomib 66 Rigel R# 66 erlotinib Tarceva ® 66 IFN α 66 ARIKACE 66 TKM ApoB 66 HuMax HepC 66 BNC# 66 elesclomol 66 dacetuzumab 66 Zysolin TM 66 protein tyrosine phosphatase 1B 66 Voreloxin 66 TRAIL R2 66 Panzem NCD 66 Daclizumab 66 HER2 antibody 66 proteasome inhibitor bortezomib 66 Naproxcinod 66 Tumor Necrosis Factor 66 FVIIa 66 CIMZIA ™ 66 telaprevir dosed 66 Amplimexon 66 PGL# 66 anticancer agent 66 ISF# 66 Phase #b/#a clinical 66 BiTE antibody 66 Cloretazine 66 active moiety 66 BAL# [001] 66 Azacitidine 66 tumor xenograft models 66 Luteinizing Hormone Releasing Hormone 66 lapatinib Tykerb 66 nucleoside analogues 66 vascular disrupting agents 66 AQ4N 66 diarrhea predominant irritable 66 DU #b 66 PEGylated interferon 66 Phase 1b clinical trials 66 Onconase 66 multi kinase inhibitor 66 MEK inhibitor RDEA# 66 Dacogen injection 66 MIRCERA 66 TELINTRA 66 Phase IIa trial 66 Actilon 66 zanolimumab 66 Decitabine 66 ZACTIMA 66 BrachySil 66 davunetide intranasal AL 66 KRN# 66 Deforolimus 66 delafloxacin 66 entinostat 66 BCR ABL inhibitors 66 luteinizing hormone releasing 66 chimeric monoclonal antibody 66 Aurora kinase inhibitor 66 ponatinib 66 posaconazole 66 generation Hsp# inhibitor 66 Tocilizumab 66 cetuximab Erbitux ® 66 INCB# [002] 66 galiximab 66 cetuximab Erbitux R 66 investigational pan BCR 66 TLR9 agonist 66 lomitapide 66 MAb 66 Cloretazine R VNP#M 66 KNS # 66 pharmacodynamic properties 66 Romiplostim 66 AMD# [003] 66 urocortin 2 66 CXB# 66 CD# CEA 66 renin inhibitors 66 IMC A# 66 ganaxolone 66 ImmunoVEX HSV2 65 volociximab 65 Aptivus ® 65 Antiviral Activity 65 ATL# [002] 65 PKC# 65 DCCR 65 DB# [003] 65 CANCIDAS 65 relapsed MM 65 oral ridaforolimus 65 Perifosine 65 inhibitor RG# 65 Omacetaxine mepesuccinate 65 DFMO 65 targeted antifolate 65 calcitonin 65 ProLindac 65 double blinded placebo 65 L BLP# 65 Squalamine 65 GLP toxicology studies 65 TriRima 65 Resten NG 65 Aurexis 65 methylnaltrexone 65 ritonavir boosted 65 dosage regimens 65 Mitoxantrone 65 hormone agonist 65 Degarelix 65 MyVax R 65 otelixizumab 65 targeting CD# 65 Oritavancin 65 Phase 2a clinical 65 Granulocyte Colony Stimulating Factor 65 VEGF Trap 65 Exelixis compounds 65 MabCampath 65 TNF Tumor Necrosis Factor 65 Dacogen decitabine 65 rilonacept 65 Aviptadil 65 teduglutide 65 rhIL 7 65 velafermin 65 nucleotide analogue 65 LEP ETU 65 L Annamycin 65 Multimeric 65 SLx 65 FLT3 65 trastuzumab DM1 T DM1 65 Inhalation Solution 65 ascending dose 65 Epanova 65 novel VDA molecule 65 farletuzumab 65 APTIVUS r 65 Eltrombopag 65 antibody MAb 65 familial amyloidotic polyneuropathy FAP 65 Denufosol 65 anti CD3 65 RAPAFLO 65 sodium thiosulfate STS 65 Durezol 65 CG# [003] 65 Cimzia ® certolizumab pegol 65 cathepsin K inhibitor 65 imatinib Gleevec ® 65 Ofatumumab 65 seliciclib CYC# 65 azacytidine 65 MDV# 65 Azedra TM 65 nanoviricide drug 65 Androxal TM 65 Monoclonal Antibody 65 PROVENGE sipuleucel T 65 JAK Inhibitor 65 docetaxel chemotherapy 65 liposomal doxorubicin 65 LymphoStat B TM 65 Telatinib 65 Ophena TM 65 pharmacokinetic profile 65 CD3 monoclonal antibody 65 ganciclovir 65 belinostat 65 Lisofylline LSF 65 tipifarnib 65 Anticalin 65 Vidofludimus 65 Arimoclomol 65 PRX # 65 pharmacokinetic interactions 65 Hsp# inhibitors 65 Irinotecan 65 azacitidine 65 Tolvaptan 65 chemically modified siRNA 65 Olaparib 65 lead Aganocide compound 65 talabostat 65 corticosteroid dexamethasone 65 TRIOLEX 65 lumiliximab 65 pharmacokinetic PK profile 65 Nanobodies ® 65 H#N# VLP vaccine 65 BZL# 65 Neulasta ® 65 ALN TTR 65 placebo controlled Phase 65 Anthim 65 MKC# MKC# PP 65 prucalopride 65 PEGylated anti 65 bispecific antibody 65 GnRH antagonist 65 oncolytic vaccine 65 oncolytic virus 65 anti leukemic 65 dose escalation Phase 65 REG1 65 placebo controlled clinical 65 intravenously administered 65 ALK inhibitor 65 IL #E 65 TKB# 65 Bicifadine 65 PI3K/Akt pathway inhibitor 65 sorafenib tablets 65 Altastaph 65 nanoviricides 65 Exherin TM 65 custirsen 65 siRNA therapeutic 65 Cardio Vascu Grow 65 Chemophase 65 Phase 1b trial 65 Ridaforolimus 65 Natalizumab 65 Atu# 65 GALNS 65 potent topoisomerase II 65 Microplasmin 65 pharmacokinetic properties 65 Tavocept 65 Lubiprostone 65 rBChE 65 aleglitazar 65 molecularly targeted 65 erythropoietic 65 phase IIb trial 65 phase IIa 65 REP# 65 Phase III Clinical Trials 65 EcoNail 65 Universal Flu Vaccine 65 Cethromycin 65 gastrointestinal stromal tumors GIST 65 humanized monoclonal 65 PORxin TM 65 torezolid 65 MYCAMINE 65 HSP# inhibitor 65 sunitinib Sutent ® 65 oral rivaroxaban 65 anticancer activity 65 subcutaneously administered 65 PHX# 65 dose cohorts 65 Ostabolin C 65 ToGA 65 HuCAL antibodies 65 PARP inhibitor 65 pharmacokinetic characteristics 65 tafamidis 65 dasatinib Sprycel ® 65 DDP# 65 Eculizumab 65 Trabectedin 65 Oral NKTR 65 radiolabeled monoclonal antibody 65 myeloma cells 65 LT NS# 65 acyclovir Lauriad R 65 HCV NS5B polymerase 65 Panzem R 65 idarubicin 65 Metastatic Melanoma 65 assessing T DM1 65 C1 INH 65 Thiarabine 65 Phase IIa clinical 65 Erlotinib 65 ADP receptor antagonist 65 recombinant subunit vaccine 65 highly selective inhibitor 64 echinocandin 64 Zybrestat 64 Phenoptin 64 chemokine receptor 64 oral JAK1 64 Parathyroid Hormone 64 Phase IIa trials 64 Alpharadin 64 octreotide implant 64 crizotinib PF # 64 Gefitinib 64 Solulin 64 gemcitabine cisplatin 64 Phase Ib clinical trials 64 ThGRF 64 atacicept 64 generation purine nucleoside 64 visilizumab 64 Excellarate 64 long acting muscarinic 64 novel prodrug 64 myeloproliferative disorders 64 aurora kinase 64 PDX pralatrexate 64 Sphingomab 64 antisense oligonucleotide 64 Fx #A 64 Valortim ® 64 Boceprevir 64 selective modulator 64 TLR agonists 64 nonclinical studies 64 TREANDA 64 biodegradable implant 64 Personalized Immunotherapy 64 Darinaparsin 64 dose escalation trial 64 BioVant 64 vWF 64 Lenocta 64 tarenflurbil 64 tumor antigen 64 NEUMUNE 64 RNA antagonist 64 ruxolitinib 64 CGEN # 64 COX Inhibiting Nitric Oxide 64 Apixaban 64 Anticalin ® 64 Angiolix 64 Phase Ia 64 ALN RSV# 64 Valortim R 64 orBec 64 menadione 64 IMGN# 64 Prodarsan ® 64 Janus Kinase 64 IL# PE#QQR 64 alpha folate receptor 64 Fibrillex TM 64 IMP# 64 BMS# 64 Palifosfamide 64 Melphalan 64 Tarceva TM 64 adecatumumab 64 noninfectious uveitis 64 Temsirolimus 64 HDAC Inhibitor 64 adipiplon 64 thrombopoietin 64 MT#/MEDI-# 64 IFN alpha 64 randomized Phase IIb 64 ZD# [001] 64 Phase #b/#a 64 preclinical studies 64 NSCLC tumors 64 chemotherapeutic drug 64 Pathway Inhibitor 64 ASONEP 64 Adalimumab 64 interferon IFN 64 adult mesenchymal stem 64 cediranib 64 RhuDex 64 vemurafenib 64 Survivin antagonist 64 NP2 Enkephalin 64 drug GLPG# 64 LymphoStat B belimumab 64 randomized Phase III 64 radiolabeled 64 regorafenib 64 Anidulafungin 64 ara C 64 Kinase Inhibitor 64 LCP Tacro 64 Imetelstat 64 intranasal formulation 64 LAF# 64 TRAIL receptor antibodies 64 dyskinesia PD LID 64 Kamada AAT 64 generation antisense 64 Valortim 64 selective orally bioavailable 64 selective inhibition 64 omacetaxine 64 brivaracetam 64 ROTARIX 64 oral antiviral 64 Scancell 64 QVA# 64 Saforis 64 nucleotide analog 64 Neuradiab 64 HCV protease inhibitors 64 XmAb 64 ORAL Sync 64 NeuVax 64 refractory gout 64 Raltegravir 64 non nucleoside 64 Pharmacokinetic Study 64 Milatuzumab 64 Icatibant 64 CCR9 64 CorVue ™ 64 POTELLIGENT ® 64 ATL/TV# 64 alfa interferon 64 Phase III Pivotal 64 stable nucleic acid 64 IDX# 64 Phase 2b Clinical Trial 64 murine monoclonal antibody 64 atrasentan 64 synthetic peptide 64 dose escalation clinical 64 castrate resistant prostate cancer 64 vivo validation 64 blinatumomab 64 Gleevec imatinib mesylate 64 Lixivaptan 64 lintuzumab 64 LHRH antagonist 64 omalizumab Xolair 64 VNP#M 64 IFN beta 64 HspE7 64 oral leukoplakia 64 S/GSK# 64 rFVIIIFc 64 RDEA# 64 imetelstat 64 Novolimus 64 Mycamine 64 alemtuzumab Campath 64 PLX# 64 Diamyd ® 64 SARMs 64 antitumor 64 mTOR inhibitor 64 PEG Interferon lambda 64 CERVARIX 64 EFAPROXYN 64 Methylnaltrexone 64 ALGRX 64 ocrelizumab 64 MAP# 64 ThermoDox R 64 reslizumab 64 ELND# 64 NS#/#A protease 64 Phase IIB 64 bactericidal activity 64 Vernakalant 64 Bafetinib 64 tumor specific antigen 64 synthetic retinoid 64 Peginterferon 64 vivo efficacy 64 TMC# [002] 64 MAbs 64 tocilizumab 64 DermaVir 64 MOZOBIL 64 MORAb 64 CDDO Im 64 leading oral taxane 64 antitumor efficacy 64 iobenguane 64 Lacosamide 64 ProSavin 64 plasma kallikrein inhibitor 64 Ambrisentan 64 lenalidomide Revlimid R 64 ORMD 64 romidepsin 64 recurrent glioblastoma multiforme 64 platelet inhibitor 64 PCK# 64 antiangiogenic activity 64 immunomodulatory 64 Zarnestra 64 PrevOnco ™ 64 relapsed multiple myeloma 64 II Clinical Trial 64 generation antisense inhibitor 64 alagebrium 64 T#I [002] 64 anti CD3 antibody 64 Aganocide 64 Locteron ® 64 pimecrolimus 64 trodusquemine 64 AAG geldanamycin analog 64 Randomized Phase II 64 cell lymphoma CTCL 64 paclitaxel Taxol 64 oral bioavailability 64 GSK# [001] 64 inhaled formulation 64 Curaxin 64 registrational trial 64 hypoxia inducible factor 64 phase 2a 64 GLYX 64 fluticasone furoate 64 OMNARIS HFA 64 efalizumab 64 SUTENT 64 Ganciclovir 64 Allogeneic 64 nucleoside reverse transcriptase inhibitor 64 bevacizumab Avastin 64 rHuPH# 64 uricase 64 AKT inhibitor 64 Actemra tocilizumab 64 Meets Primary Endpoint 64 latanoprost 64 EGF receptor 64 INS# [001] 64 XL# [003] 64 recombinant polyclonal antibody 64 Azixa 64 aflibercept 64 partial agonist 64 Phase IIb trials 64 DEB# 64 Etoposide 64 Hsp# inhibitor 64 AEGR 64 TRC# 64 Lodotra TM 64 LAB CGRP 64 oral renin inhibitor 64 intravesical instillation 64 trabedersen 64 LNPs 64 HER2 receptor 64 HIF PHI 64 P#X# 64 Lu AA# 64 alpha 2a 64 Liraglutide 64 amrubicin 64 ANAVEX #-# [003] 64 OncoGel 64 Tacrolimus 64 afamelanotide 64 potent anti angiogenic 64 Initiate Phase 64 Fludara 64 NEUVENGE 64 alefacept 64 dosing cohort 64 telomerase therapeutic 64 Pemetrexed 64 vitro cytotoxicity 64 ALN PCS 64 Epidermal Growth Factor Receptor 64 pharmacokinetic PK 64 GPIIb IIIa 64 chemotherapeutic agent 64 next generation URAT1 64 DepoVax ™ 64 velafermin belinostat 64 ISTODAX 63 iniparib 63 adecatumumab MT# 63 iclaprim 63 fluoropyrimidine 63 rituximab Rituxan 63 Myelodysplastic Syndrome MDS 63 RSD# 63 non nucleoside inhibitor 63 EVIZON 63 oral salmon calcitonin 63 mecamylamine 63 anti amnesic 63 randomized controlled Phase 63 Fidaxomicin 63 Elvitegravir 63 Revimmune 63 Nexavar sorafenib 63 EndoTAG TM 63 nanoviricide 63 cidofovir

Back to home page